Immunophotonics to Present at the 2024 ThinkEquity Conference
28 oct. 2024 08h30 HE
|
Immunophotonics, Inc.
Immunophotonics to Present at the 2024 ThinkEquity Conference
Immunophotonics Announces Issuance of U.S. Patent Covering Lead Drug Candidate
14 sept. 2021 08h00 HE
|
Immunophotonics, Inc.
ST. LOUIS and BERN, Switzerland, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Immunophotonics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary...
Immunophotonics Announces First Patient Treated in Clinical Study Evaluating IP-001 in Patients with Advanced Solid Tumors
10 nov. 2020 01h08 HE
|
Immunophotonics, Inc.
ST. LOUIS and BERN, Switzerland, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. announces the first patient treated in the phase 1b/2a clinical trial examining IP-001 in thermally ablated...
Immunophotonics Announces Appointment of Jonathan Knowles to Board of Directors
05 oct. 2020 10h13 HE
|
ImmunoPhotonics, Inc.
ST. LOUIS, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc., a biotechnology company focused on the discovery and development of proprietary immune-activating carbohydrate polymers for the...
Immunophotonics Announces Appointment of Jonathan Knowles to Board of Directors
05 oct. 2020 04h13 HE
|
ImmunoPhotonics, Inc.
BERN, Switzerland, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc., a biotechnology company focused on the discovery and development of proprietary immune-activating carbohydrate polymers...
Immunophotonics, Inc. Announces First Patient Dosed in a Randomized, Controlled Breast Cancer Clinical Trial for inCVAX – A Novel Investigational Immuno-Oncology Therapy
23 août 2016 09h17 HE
|
ImmunoPhotonics, Inc.
ST. LOUIS, Aug. 23, 2016 (GLOBE NEWSWIRE) -- Immunophotonics today announces that it has dosed its first patient in a randomized & controlled clinical trial to further evaluate the efficacy of...